Evidence map›Paper›PMID 40584317›Full record

ArticleACS omega2025

Computational Structural Comparison of Toxoplasma gondii CDPK1 and Human BUB1 kinases: Implications for Selective Inhibitor Design.

João Pedro Bezerra Carvalho, Deborah Antunes, Daniel Adesse, Ana Carolina Guimarães

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

João Pedro Bezerra CarvalhoLaboratory for Applied Genomics and Bioinnovations, Oswaldo Cruz Institute (IOC - FIOCRUZ), Rio de Janeiro 21040-900, Brazil.
Deborah AntunesLaboratory for Applied Genomics and Bioinnovations, Oswaldo Cruz Institute (IOC - FIOCRUZ), Rio de Janeiro 21040-900, Brazil.ORCID https://orcid.org/0000-0002-2927-0800
Daniel AdesseStructural Biology laboratory, Oswaldo Cruz Institute (IOC - FIOCRUZ), Rio de Janeiro 21040-900, Brazil.ORCID https://orcid.org/0000-0002-7421-9510
Ana Carolina GuimarãesLaboratory for Applied Genomics and Bioinnovations, Oswaldo Cruz Institute (IOC - FIOCRUZ), Rio de Janeiro 21040-900, Brazil.ORCID https://orcid.org/0000-0003-1260-543X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxoplasmosis, affecting one-third of the global human population, urgently requires new therapeutic strategies due to current treatment limitations and drug resistance. Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) is a promising drug target due to its essential role in parasite survival and its presumed unique glycine gatekeeper residue. Aiming at identifying new and selective inhibitors of TgCDPK1, we performed computational structural analyses and unexpectedly found that a human kinase (BUB1), despite having only 14% sequence identity, shares this glycine gatekeeper with TgCDPK1, which initially raised concerns for selective inhibitor development. Subsequent analyses revealed distinct electrostatic properties and binding site architectures between these kinases. Molecular dynamics simulations demonstrate differential binding pocket dynamics, with TgCDPK1 showing more focused interaction networks compared to BUB1's dispersed patterns. Virtual screening of apicomplexan kinase inhibitors confirms stronger binding affinity for TgCDPK1 over BUB1, supporting the continued development of selective therapeutics against toxoplasmosis.

Identifiers

PMID40584317
PMCPMC12199047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.